Collegium Pharmaceutical (COLL): 100% TSR Pharma with a call option worth 80-100% TSR more
Current Price: ~$29-30 | 36-month Target Price: ~$48, TSR: 100% | COLL Join the mailing list for future blogs: Click here Model: Available to download here ( https://docs.google.com/spreadsheets/d/1VLzZ567r-R7vpl192fMB5vbgxcSpctXL/edit?usp=sharing&ouid=100501050702536154043&rtpof=true&sd=true ) Overlooked pharma company which can generate enough cash to purchase all shares within the next 6-7 years at current price levels Company & Industry Overview Collegium pharmaceuticals was founded by Michael Heffernan who stepped down as CEO mid 2018 when Joe Ciaffoni took over. He has since stepped down and Michael Heffernan who stayed on Chairman has become interim CEO. Michael will now be succeeded by Vikram Karnani, who grew Horizon sales from $300m to $4b in 9 years before acquisition by Amgen. Collegium markets extensive release opioid pain medications. Important note: Collegium was named, but subsequently dismissed with prejudice of any opioid related litigat